News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|October 19, 2021

Patient Case #2 Continued: Novel Second-Generation Antipsychotics

Author(s)Michael E. Thase, MD, Gustavo Alva, MD, DFAPA, Theresa Cerulli, MD

A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.

Episodes in this series

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 3 Clinical Impressions From Patient Case #1

EP. 3 Clinical Impressions From Patient Case #1

EP. 4 Diagnosis of Bipolar Disorder

EP. 4 Diagnosis of Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 8 Role of Telemedicine in Bipolar Disorder

EP. 8 Role of Telemedicine in Bipolar Disorder

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

February theme

Presenting Our February 2026 Theme: Bipolar Disorder

February 2nd 2026

bipolar

Phase 2 Trial Initiated: LB-102 for Bipolar Depression

January 26th 2026

brain

sNDA Submission: Igalmi for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia in Outpatient Setting

January 20th 2026

New Year’s Resolutions and Bipolar Disorder: Insights from Jo Hughes, DSMc, PA-C, CAQ-PSYCH

ByJo A. Hughes, DMSc, PA-C, CAQ-PSY,Jessica Walters

January 1st 2026

Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics

ByJessica Walters

December 24th 2025

Latest CME

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Trending on Psychiatric Times

Sacred Cows and Shibboleths: Why Western Psychiatry Is Shackled and How Global Social Psychiatry May Save It

Data Centers Are Swallowing Up Our Human Resources

Depression and Long COVID Outcomes in Women: New Data Analysis

Data Supports Potential of Negative Allosteric Modulators for Anxiety and Fear-Related Disorders

A New Era of Mental Health: Increasing Youth Access to the 988 Lifeline and Campus Suicide Prevention